ATE424402T1 - Imidazopyridinverbindungen - Google Patents

Imidazopyridinverbindungen

Info

Publication number
ATE424402T1
ATE424402T1 AT06738924T AT06738924T ATE424402T1 AT E424402 T1 ATE424402 T1 AT E424402T1 AT 06738924 T AT06738924 T AT 06738924T AT 06738924 T AT06738924 T AT 06738924T AT E424402 T1 ATE424402 T1 AT E424402T1
Authority
AT
Austria
Prior art keywords
compounds
imidazopyridine compounds
crf1
formula
treatment
Prior art date
Application number
AT06738924T
Other languages
English (en)
Inventor
Heather Barbosa
Elizabeth Collins
Chafiq Hamdouchi
Erik Hembre
Philip Hipskind
Richard Johnston
Jianliang Lu
Michael Rupp
Takako Takakuwa
Richard Thompson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE424402T1 publication Critical patent/ATE424402T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
AT06738924T 2005-03-21 2006-03-20 Imidazopyridinverbindungen ATE424402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66381605P 2005-03-21 2005-03-21

Publications (1)

Publication Number Publication Date
ATE424402T1 true ATE424402T1 (de) 2009-03-15

Family

ID=36753943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06738924T ATE424402T1 (de) 2005-03-21 2006-03-20 Imidazopyridinverbindungen

Country Status (25)

Country Link
US (1) US7612067B2 (de)
EP (1) EP1869049B1 (de)
JP (1) JP4971300B2 (de)
KR (1) KR20070120963A (de)
CN (1) CN101142217B (de)
AT (1) ATE424402T1 (de)
AU (1) AU2006227300B2 (de)
BR (1) BRPI0608857A2 (de)
CA (1) CA2600478C (de)
CR (1) CR9389A (de)
CY (1) CY1109069T1 (de)
DE (1) DE602006005477D1 (de)
DK (1) DK1869049T3 (de)
EA (1) EA012393B1 (de)
ES (1) ES2321446T3 (de)
IL (1) IL185014A0 (de)
MA (1) MA29437B1 (de)
MX (1) MX2007011600A (de)
NO (1) NO20074961L (de)
PL (1) PL1869049T3 (de)
PT (1) PT1869049E (de)
SI (1) SI1869049T1 (de)
TN (1) TNSN07358A1 (de)
WO (1) WO2006102194A1 (de)
ZA (1) ZA200706715B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
MX2008016542A (es) 2006-06-30 2009-01-19 Novartis Ag Derivados de quinolina y sus composiciones farmaceuticas.
WO2008036541A1 (en) * 2006-09-20 2008-03-27 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
WO2009013335A1 (en) 2007-07-26 2009-01-29 Novartis Ag Organic compounds
US20100331333A1 (en) * 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN101981033B (zh) 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
SG10201900514RA (en) 2008-10-22 2019-02-27 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2391619A1 (de) * 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroarylverbindungen und ihre verwendung als pi3k-inhibitoren
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2493472B1 (de) * 2009-10-26 2016-12-07 Signal Pharmaceuticals, LLC Verfahren zur synthese und reinigung von heteroarylverbindungen
EA020847B1 (ru) * 2009-10-30 2015-02-27 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN101830909A (zh) * 2010-04-26 2010-09-15 西安近代化学研究所 4氢-环戊[2,1-b;3,4-b′]双噻吩酮的制备方法
BR112012029405B1 (pt) 2010-05-20 2021-01-05 Array Biopharma Inc. compostos macrocíclicos como inibidores de trk quinase, composição farmacêutica, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação de um composto
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR082665A1 (es) 2010-08-11 2012-12-26 Millennium Pharm Inc Derivados heteroarilicos inhibidores de quinasas pi3k, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos proliferativos, inflamatorios y/o cardiovasculares
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
DE102011075398A1 (de) * 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013064445A1 (en) * 2011-11-01 2013-05-10 F. Hoffmann-La Roche Ag Imidazopyridazine compounds
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
JP6174695B2 (ja) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ．ベー． ホスホジエステラーゼ１０酵素の阻害剤
EP2746256A1 (de) 2012-12-19 2014-06-25 Basf Se Fungizidimidazolyl- und -triazolylverbindungen
WO2014095381A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746279A1 (de) 2012-12-19 2014-06-25 Basf Se Fungizidimidazolyl- und -triazolylverbindungen
EP2746277A1 (de) 2012-12-19 2014-06-25 Basf Se Fungizidimidazolyl- und -triazolylverbindungen
EP2746264A1 (de) 2012-12-19 2014-06-25 Basf Se Substituierte [1,2,4]-Triazol- und Imidazolverbindungen
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746255A1 (de) 2012-12-19 2014-06-25 Basf Se Substituierte [1,2,4]-Triazol- und Imidazolverbindungen
EP2746257A1 (de) 2012-12-21 2014-06-25 Basf Se Substituierte [1,2,4]Triazol- und Imidazolverbindungen
EP2746259A1 (de) 2012-12-21 2014-06-25 Basf Se Substituierte [1,2,4]Triazol- und Imidazolverbindungen
EP2746260A1 (de) 2012-12-21 2014-06-25 Basf Se Substituierte [1,2,4]Triazol- und Imidazolverbindungen
EP2746258A1 (de) 2012-12-21 2014-06-25 Basf Se Substituierte [1,2,4]Triazol- und Imidazolverbindungen
CN103058933B (zh) * 2012-12-29 2015-06-17 泉州师范学院 一种6-甲基-3-氨基哒嗪的工业化制备方法
IL304134B2 (en) 2014-01-21 2025-04-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
IL290905B2 (en) 2014-11-16 2023-09-01 Array Biopharma Inc Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3439662B1 (de) 2016-04-04 2024-07-24 Loxo Oncology, Inc. Flüssige formulierungen von (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
LT3800189T (lt) 2016-05-18 2023-10-10 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
WO2018050286A1 (en) * 2016-09-16 2018-03-22 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Traf 6 inhibitors
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
TWI803504B (zh) * 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
BR112020024062A2 (pt) 2018-04-27 2021-02-09 Spruce Biosciences, Inc. métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
EP4656192A3 (de) 2020-08-12 2026-03-11 Spruce Biosciences, Inc. Tildacerfont und derivate davon zur behandlung des polyzystischen ovarialsyndroms
CN113651762B (zh) * 2021-09-03 2023-12-26 上海晋鲁医药科技有限公司 一种1-甲基-1h-1,2,4-三氮唑-3-甲酸甲酯的制备方法
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336495T1 (de) * 1996-02-07 2006-09-15 Neurocrine Biosciences Inc Pyrazolopyrimidine als crf rezeptor-antagonisten
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
GB0017543D0 (en) * 2000-07-17 2000-09-06 Merck Sharp & Dohme Therapeutic agents
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
TWI327462B (en) 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
JP4403105B2 (ja) * 2002-01-18 2010-01-20 住友化学株式会社 イミダゾピリダジン誘導体
JP2003313176A (ja) * 2002-04-24 2003-11-06 Sankyo Co Ltd アミノアゾール誘導体

Also Published As

Publication number Publication date
DK1869049T3 (da) 2009-05-18
US7612067B2 (en) 2009-11-03
SI1869049T1 (sl) 2009-08-31
EP1869049B1 (de) 2009-03-04
CA2600478A1 (en) 2006-09-28
WO2006102194A1 (en) 2006-09-28
EA200702044A1 (ru) 2008-02-28
JP2008533201A (ja) 2008-08-21
PL1869049T3 (pl) 2009-07-31
BRPI0608857A2 (pt) 2012-08-28
AU2006227300A1 (en) 2006-09-28
CR9389A (es) 2007-12-07
DE602006005477D1 (en) 2009-04-16
MX2007011600A (es) 2007-12-07
MA29437B1 (fr) 2008-05-02
CY1109069T1 (el) 2014-07-02
PT1869049E (pt) 2009-05-26
EP1869049A1 (de) 2007-12-26
IL185014A0 (en) 2007-12-03
JP4971300B2 (ja) 2012-07-11
KR20070120963A (ko) 2007-12-26
CA2600478C (en) 2013-02-05
ZA200706715B (en) 2008-10-29
AU2006227300B2 (en) 2012-02-02
CN101142217B (zh) 2010-12-08
NO20074961L (no) 2007-10-17
US20080113978A1 (en) 2008-05-15
CN101142217A (zh) 2008-03-12
TNSN07358A1 (en) 2008-12-31
ES2321446T3 (es) 2009-06-05
EA012393B1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
ATE424402T1 (de) Imidazopyridinverbindungen
MX2009003125A (es) Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
MX2009003098A (es) Compuestos de tiofen pirazolopirimidina.
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
TW200730525A (en) Therapeutic agents
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
TW200611701A (en) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1869049

Country of ref document: EP